{"text": "每天2次以上胰岛素注射时原则上不联用胰岛素促泌剂(对于肥胖且胰岛素用量较大，已联合上述药物治疗效果不满意者，可试用GLP-1受体激动剂)。", "spo_list": [{"object": {"@value": "胰岛素"}, "object_type": {"@value": "Drug"}, "predicate": "Frequency_Drug", "subject": "每天2次", "subject_type": "Frequency"}, {"object": {"@value": "肥胖"}, "object_type": {"@value": "Disease"}, "predicate": "Drug_Disease", "subject": "胰岛素", "subject_type": "Drug"}]}
{"text": "这为我国2型糖尿病忠者降糖治疗提供了一种新的选择。", "spo_list": [{"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "2型", "subject_type": "Class"}]}
{"text": "·糖尿病合开各种严重慢性开发症如各种神经病变、视网膜病变、肾病、糖尿病足溃疡伴或不伴感染等；", "spo_list": [{"object": {"@value": "神经病变"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "神经", "subject_type": "Anatomy"}, {"object": {"@value": "视网膜病变"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "视网膜", "subject_type": "Anatomy"}, {"object": {"@value": "肾病"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "肾", "subject_type": "Anatomy"}, {"object": {"@value": "糖尿病足溃疡"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "足", "subject_type": "Anatomy"}]}
{"text": "3.运动治疗与儿童减肥：一筒纳入了2项Meta分析的系统性综述，均显示体脂率有显著性降低。而其他肥胖指标(BMI、体重、中心性肥胖)则没有显著性差异。一篇纳入40项研究的系统性综述和Meta分析，评价了抗阻训练对肥胖儿童力量、体成分等的影响，显示抗阻运动对体成分有极小影响，且亚组分析显示运动量越大、年龄越小、随机对照设计产生更显著效果。一项纳入15个随机对照试验的系统性综述和Meta分析，比较仅饮食干预与饮食结合运动或仅运动干预对超重儿童减重和降低代谢风险的效果，结果显示，短期干预中仅饮食和饮食结合运动均产生了减重和代谢指标改善的效果，而长期干预显示饮食结合运动干预可以显著改善高密度脂蛋白胆固醇和空腹血糖、空腹胰岛素水平。", "spo_list": [{"object": {"@value": "肥胖"}, "object_type": {"@value": "Disease"}, "predicate": "Treatment_Disease", "subject": "抗阻训练", "subject_type": "Treatment"}, {"object": {"@value": "超重"}, "object_type": {"@value": "Disease"}, "predicate": "Treatment_Disease", "subject": "饮食干预", "subject_type": "Treatment"}, {"object": {"@value": "超重"}, "object_type": {"@value": "Disease"}, "predicate": "Treatment_Disease", "subject": "运动干预", "subject_type": "Treatment"}, {"object": {"@value": "超重"}, "object_type": {"@value": "Disease"}, "predicate": "Test_items_Disease", "subject": "高密度脂蛋白胆固醇", "subject_type": "Test_items"}, {"object": {"@value": "超重"}, "object_type": {"@value": "Disease"}, "predicate": "Test_items_Disease", "subject": "空腹血糖", "subject_type": "Test_items"}, {"object": {"@value": "超重"}, "object_type": {"@value": "Disease"}, "predicate": "Test_items_Disease", "subject": "空腹胰岛素", "subject_type": "Test_items"}, {"object": {"@value": "超重"}, "object_type": {"@value": "Disease"}, "predicate": "Treatment_Disease", "subject": "饮食结合运动", "subject_type": "Treatment"}]}
{"text": "(3)糖尿病周围神经病变(DPN)的诊断：DPN是指在排除其他原因的情况下，糖尿病患者出现周障碍相关的症状或体征，其中最常见及最具代尿病远端对称性多发性神经病变(DSPN)。", "spo_list": [{"object": {"@value": "糖尿病周围神经病变(DPN)"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "周围神经", "subject_type": "Anatomy"}, {"object": {"@value": "尿病远端对称性多发性神经病变(DSPN)"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "神经", "subject_type": "Anatomy"}]}
{"text": "7.二甲双胍联合TZDs的疗效：二甲双胍联合TZDs能更好地降低HbA1c，显著改善胰岛功能和IR，但联合治疗药物的不良反应(体重增加、升高LDL-C)高于单用二甲双胍；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著。故IR严重的患者可考虑二甲双胍联合TZDs药物的治疗方案(I级)。", "spo_list": [{"object": {"@value": "二甲双胍"}, "object_type": {"@value": "Drug"}, "predicate": "ADE_Drug", "subject": "体重增加", "subject_type": "ADE"}, {"object": {"@value": "二甲双胍"}, "object_type": {"@value": "Drug"}, "predicate": "ADE_Drug", "subject": "升高LDL-C", "subject_type": "ADE"}, {"object": {"@value": "TZDs"}, "object_type": {"@value": "Drug"}, "predicate": "ADE_Drug", "subject": "体重增加", "subject_type": "ADE"}, {"object": {"@value": "TZDs"}, "object_type": {"@value": "Drug"}, "predicate": "ADE_Drug", "subject": "升高LDL-C", "subject_type": "ADE"}, {"object": {"@value": "二甲双胍"}, "object_type": {"@value": "Drug"}, "predicate": "ADE_Drug", "subject": "体重增加", "subject_type": "ADE"}, {"object": {"@value": "二甲双胍"}, "object_type": {"@value": "Drug"}, "predicate": "ADE_Drug", "subject": "升高LDL-C", "subject_type": "ADE"}, {"object": {"@value": "IR"}, "object_type": {"@value": "Disease"}, "predicate": "Drug_Disease", "subject": "二甲双胍", "subject_type": "Drug"}, {"object": {"@value": "IR"}, "object_type": {"@value": "Disease"}, "predicate": "Drug_Disease", "subject": "TZDs", "subject_type": "Drug"}]}
{"text": "长效制剂有利拉鲁肽，每天一次；艾塞那肽周制剂，每周一次；阿必鲁肽(albiglutide)，每周一次；dulaglutide，每周一次。", "spo_list": [{"object": {"@value": "利拉鲁肽"}, "object_type": {"@value": "Drug"}, "predicate": "Frequency_Drug", "subject": "每天一次", "subject_type": "Frequency"}, {"object": {"@value": "艾塞那肽周制剂"}, "object_type": {"@value": "Drug"}, "predicate": "Frequency_Drug", "subject": "每周一次", "subject_type": "Frequency"}, {"object": {"@value": "阿必鲁肽(albiglutide)"}, "object_type": {"@value": "Drug"}, "predicate": "Frequency_Drug", "subject": "每周一次", "subject_type": "Frequency"}, {"object": {"@value": "dulaglutide"}, "object_type": {"@value": "Drug"}, "predicate": "Frequency_Drug", "subject": "每周一次", "subject_type": "Frequency"}]}
{"text": "心血管疾病与糖尿病关系密切。2006年的”中国心脏调查”发现，慢性稳定性心绞痛和急性冠状动脉综合征(ACS)的住院患者中，约80%存在不同程度的糖代谢异常，其中糖尿病占52.9%，糖尿病前期占26.4%。中国医院门诊高血压患者中，糖尿病患病率为24.3%。中华医学会糖尿病学分会慢性并发症调查组报告，1991—2000年部分三级甲等医院住院的2型糖尿病患者合并高血压者占34.2%，合并其他心血管疾病者占17.1%。荟萃分析表明，糖化血红蛋白(HbA1c)在5%以上的患者，HbA1c每增加1%，心血管事件风险增加21%。", "spo_list": [{"object": {"@value": "心血管疾病"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "心血管", "subject_type": "Anatomy"}, {"object": {"@value": "慢性稳定性心绞痛"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "心", "subject_type": "Anatomy"}, {"object": {"@value": "慢性稳定性心绞痛"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "慢性", "subject_type": "Class"}, {"object": {"@value": "慢性稳定性心绞痛"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "稳定性", "subject_type": "Class"}, {"object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "急性", "subject_type": "Class"}, {"object": {"@value": "急性冠状动脉综合征(ACS)"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "冠状动脉", "subject_type": "Anatomy"}, {"object": {"@value": "糖尿病前期"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "前期", "subject_type": "Class"}, {"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "2型", "subject_type": "Class"}, {"object": {"@value": "心血管疾病"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "心血管", "subject_type": "Anatomy"}, {"object": {"@value": "心血管事件"}, "object_type": {"@value": "Disease"}, "predicate": "Test_items_Disease", "subject": "糖化血红蛋白(HbA1c)", "subject_type": "Test_items"}, {"object": {"@value": "心血管事件"}, "object_type": {"@value": "Disease"}, "predicate": "Test_items_Disease", "subject": "HbA1c", "subject_type": "Test_items"}, {"object": {"@value": "心血管事件"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "心血管", "subject_type": "Anatomy"}]}
{"text": "6.非酒精性脂肪肝病(NAFLD)：2型糖尿病患儿25%~50%合并有NAFLD，故糖尿病一经诊断即需对此相应评估，包括肝脏B超或磁共振肝脏脂肪定量等，以后每年1次。对于有胰岛素抵抗的患儿，控制体重及口服二甲双胍均能降低肝酶，改善NAFLD。护肝药虽可用于肝功能损伤，但对于2型糖尿病合并NAFLD的青少年，最佳方法还是改善胰岛素抵抗。", "spo_list": [{"object": {"@value": "非酒精性脂肪肝病(NAFLD)"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "肝", "subject_type": "Anatomy"}, {"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "2型", "subject_type": "Class"}, {"object": {"@value": "糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Test_Disease", "subject": "肝脏B超", "subject_type": "Test"}, {"object": {"@value": "糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Test_Disease", "subject": "磁共振肝脏脂肪定量", "subject_type": "Test"}, {"object": {"@value": "NAFLD"}, "object_type": {"@value": "Disease"}, "predicate": "Test_items_Disease", "subject": "肝酶", "subject_type": "Test_items"}, {"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "2型", "subject_type": "Class"}, {"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Pathogenesis_Disease", "subject": "胰岛素抵抗", "subject_type": "Pathogenesis"}, {"object": {"@value": "二甲双胍"}, "object_type": {"@value": "Drug"}, "predicate": "Method_Drug", "subject": "口服", "subject_type": "Method"}, {"object": {"@value": "肝功能损伤"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "肝", "subject_type": "Anatomy"}]}
